ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7

[1]  G. Ning,et al.  The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism , 2013, PloS one.

[2]  Jing-Ping Zhou,et al.  Inhibitory effect of ARHI on pancreatic cancer cells and NF-κB activity. , 2013, Molecular medicine reports.

[3]  Mauro Piacentini,et al.  mTOR inhibits autophagy by controlling ULK1 ubiquitylation, self-association and function through AMBRA1 and TRAF6 , 2013, Nature Cell Biology.

[4]  Yin Xiao,et al.  Vertical inhibition of the PI3K/Akt/mTOR pathway for the treatment of osteoarthritis , 2013, Journal of cellular biochemistry.

[5]  Xiaohong Wu,et al.  Effect of ARHI on lung cancer cell proliferation, apoptosis and invasion in vitro , 2013, Molecular Biology Reports.

[6]  N. Reiner,et al.  Class IA Phosphatidylinositol 3-Kinase p110α Regulates Phagosome Maturation , 2012, PloS one.

[7]  Mudan Lu,et al.  The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer , 2012, Medical Oncology.

[8]  Y. Li,et al.  Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells , 2012, Tumor Biology.

[9]  R. Bast,et al.  The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways , 2012, Oncogene.

[10]  G. Rosner,et al.  Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy , 2011, Cancer.

[11]  F. Sinicrope,et al.  Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1* , 2011, The Journal of Biological Chemistry.

[12]  Michael J. Clague,et al.  Met Receptor: A Moving Target , 2011, Science Signaling.

[13]  M. Hung,et al.  Deciphering the role of forkhead transcription factors in cancer therapy. , 2011, Current drug targets.

[14]  S. Gridley,et al.  Study of the PDK1/AKT signaling pathway using selective PDK1 inhibitors, HCS, and enhanced biochemical assays. , 2011, Analytical biochemistry.

[15]  Xuejun Jiang,et al.  Distinct autophagosomal-lysosomal fusion mechanism revealed by thapsigargin-induced autophagy arrest. , 2011, Molecular cell.

[16]  Lin Zhou,et al.  Akt-FOXO3a signaling axis dysregulation in human oral squamous cell carcinoma and potent efficacy of FOXO3a-targeted gene therapy. , 2011, Oral oncology.

[17]  R. DePinho,et al.  Deacetylation of FoxO by Sirt1 Plays an Essential Role in Mediating Starvation-Induced Autophagy in Cardiac Myocytes , 2010, Circulation research.

[18]  R. Dahiya,et al.  MicroRNAs 221/222 and Genistein-Mediated Regulation of ARHI Tumor Suppressor Gene in Prostate Cancer , 2010, Cancer Prevention Research.

[19]  Á. Tósaki,et al.  Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. , 2010, Canadian journal of physiology and pharmacology.

[20]  Lara J. Monteiro,et al.  Constitutively Nuclear FOXO3a Localization Predicts Poor Survival and Promotes Akt Phosphorylation in Breast Cancer , 2010, PloS one.

[21]  R. Bast,et al.  Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. , 2010, Molecular medicine reports.

[22]  M. Ahmadian,et al.  Duplication of Glu37 in the switch I region of HRAS impairs effector/GAP binding and underlies Costello syndrome by promoting enhanced growth factor-dependent MAPK and AKT activation. , 2010, Human molecular genetics.

[23]  A. Nysted,et al.  LOH at 1p31 (ARHI) and Proliferation in Lymph Node-Negative Breast Cancer , 2009, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[24]  R. Shaker,et al.  Altered mechanosensitive properties of vagal afferent fibers innervating the stomach following gastric surgery in rats , 2009, Neuroscience.

[25]  A. Meléndez,et al.  Autophagy in C. elegans. , 2009, WormBook : the online review of C. elegans biology.

[26]  Arunima Sengupta,et al.  FoxO Transcription Factors Promote Autophagy in Cardiomyocytes* , 2009, The Journal of Biological Chemistry.

[27]  C. Jung,et al.  ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. , 2009, Molecular biology of the cell.

[28]  G. Rosenberger,et al.  Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome , 2009, Human mutation.

[29]  R. Deng,et al.  [A G-quadruplex ligand SYUIQ-5 induces autophagy by inhibiting the Akt-FOXO3a pathway in nasopharyngeal cancer cells]. , 2009, Ai zheng = Aizheng = Chinese journal of cancer.

[30]  Zhen Lu,et al.  The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. , 2008, The Journal of clinical investigation.

[31]  F. Cecconi,et al.  The role of autophagy in mammalian development: cell makeover rather than cell death. , 2008, Developmental cell.

[32]  J. Guan,et al.  FIP200, a ULK-interacting protein, is required for autophagosome formation in mammalian cells , 2008, The Journal of cell biology.

[33]  G. Mills,et al.  ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation , 2008, Nature Cell Biology.

[34]  Michael McClelland,et al.  Survey of differentially methylated promoters in prostate cancer cell lines. , 2005, Neoplasia.

[35]  T. Liloglou,et al.  Methylation discriminators in NSCLC identified by a microarray based approach. , 2005, International journal of oncology.

[36]  G. Cottrell,et al.  c-Cbl Mediates Ubiquitination, Degradation, and Down-regulation of Human Protease-activated Receptor 2* , 2005, Journal of Biological Chemistry.

[37]  C. Plass,et al.  Silencing of the maternally imprinted tumor suppressor ARHI contributes to follicular thyroid carcinogenesis. , 2005, The Journal of clinical endocrinology and metabolism.

[38]  W. Voigt.  Sulforhodamine B assay and chemosensitivity. , 2005, Methods in molecular medicine.

[39]  Ajay N. Jain,et al.  Expression of the Tumor Suppressor Gene ARHI in Epithelial Ovarian Cancer Is Associated with Increased Expression of p21WAF1/CIP1 and Prolonged Progression-Free Survival , 2004, Clinical Cancer Research.

[40]  P. Saftig,et al.  Role for Rab7 in maturation of late autophagic vacuoles , 2004, Journal of Cell Science.

[41]  M. Colombo,et al.  Rab7 is required for the normal progression of the autophagic pathway in mammalian cells , 2004, Journal of Cell Science.

[42]  Ryuji Kobayashi,et al.  IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a , 2004, Cell.

[43]  Ryuji Kobayashi,et al.  IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. , 2004, Cell.

[44]  M. von Zastrow,et al.  A Novel Endocytic Recycling Signal That Distinguishes the Membrane Trafficking of Naturally Occurring Opioid Receptors* , 2003, Journal of Biological Chemistry.

[45]  Gordon B Mills,et al.  ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers , 2003, Oncogene.

[46]  C. Thompson,et al.  Akt Activation Promotes Degradation of Tuberin and FOXO3a via the Proteasome* , 2003, The Journal of Biological Chemistry.

[47]  L. Collinson,et al.  JCB Article , 2001 .

[48]  D. Lambright,et al.  The FYVE Domain of Early Endosome Antigen 1 Is Required for Both Phosphatidylinositol 3-Phosphate and Rab5 Binding , 2000, The Journal of Biological Chemistry.

[49]  J W Gray,et al.  NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. , 1999, Proceedings of the National Academy of Sciences of the United States of America.